Clinical Trial Update: Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients [Phase 1]

View source ↗

Summary

A completed Phase 1 trial assessed histologic effects and safety of pre/post-operative IL13-PE38QQR in patients with recurrent resectable supratentorial maligna…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Astrocytoma
• Glioblastoma Multiforme
• Malignant Astrocytoma
• Malignant Glioma
• Oligoastrocytoma

Drugs mentioned

• IL13-PE38QQR

Snippet

Sponsor: INSYS Therapeutics Inc | Conditions: Malignant Glioma, Glioblastoma Multiforme | Phase 1 | Status: COMPLETED